Anti-thyroid drugs or131I therapy to control the hyperthyroidism of Graves disease: A cost-effectiveness analysis;Tratamento clínico com drogas antitireoidianas ou dose terapêutica de iodo-131 no controle do hipertireoidismo na doença de graves: Avaliação dos custos e benefícios

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 6, 2006, Pages 1096-1101

  Cruz Jr , Antônio Fiel ^a,b   Takahashi, Míriam Hideco ^a   Albino, Cláudio Cordeiro ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b NONE   (Brazil)

Author keywords

131iodine; Anti thyroid drugs; Cost effectiveness; Graves disease; Hyperthyroidism

Indexed keywords

ANTITHYROID AGENT; RADIOACTIVE IODINE; THIAMAZOLE;

ADOLESCENT; ADULT; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTITHYROID AGENTS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MALE; METHIMAZOLE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846350952     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000600017     Document Type: Article

References (12)

1. Spencer RP. Radioiodine therapy of hyperthyroidism: socio-economic considerations. J Nucl Med 1985;26:663-5.
2. Leese GP, Jung RT, Guthrie C, Waugh N, Browning MCK. Morbidity in patients on L-thyroxine: a comparison of those with normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 1992;37:500-3.
3. Wartofsky L, Glinoer D, Solomon B, Lagasse R. Differences and similarities in the treatment of diffuse goiter in Europe and the United States. Exp Clin Endocrinol 1991;97:243-51.
4. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, et al. Administration of thyroxine in treated Graves' disease: effect on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991;324:947-53.
5. McIver B, Rea P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996;334:220-4.
6. Hardisty CA, Jones SJ, Hedley AJ, Munro DS, Bewsher PD, Weir RD. Clinical outcome and costs of care in radioiodine treatment of hyperthyroidism. J R Coll Physicians Lon 1990;24:36-42.
7. Ljunggren JG, Torring O, Wallin G, Taube A, Tallstedt L, Hamberger B, et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998;8:653-9.
8. Tominaga T, Yokoyama N, Nagataki S, Cho BY, Koh C-S, Chen J-L, et al. International differences in approaches to 131I therapy for Grave's disease: case selection and restrictions recommended to patients in Japan, Korea, and China. Thyroid 1997;7:217-20.
9. Wartofsky L. Radioiodine therapy for Graves' disease: case selection and restrictions recommended to patients in North America. Thyroid 1997;7:213-6.
10. Romaldini JH. Case selection and restrictions recommended to patients with hyperthyroidism in South America. Thyroid 1997;7:225-8.
11. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994;330:1731-8.
12. Lazarus JH, Reinwein D, Benker G, Alexandrer WD. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. J Clin Endocrinol Metab 1993;76:1516-21.